Skip to main content

Table 4 Five-year actuarial rates of local-regional control according to clinical and pathologic disease status by molecular subtype

From: Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy

Factor HR+/HER2-
(n= 309)
HR+/HER2+
(n= 51)
HR-/HER2+
(n= 42)
HR-/HER2-
(n= 193)
P-value
Clinical stage      
I/II (n = 473) 98% 95% 86% 91% 0.004
III (n = 120) 92% 100% 89% 84% 0.25
Number positive nodes*      
0 to 3 (n = 517) 98% 95% 89% 91% 0.007
≥ 4 (n = 75) 93% 100% 67% 56% 0.001
pCR      
No (n = 471) 97% 95% 83% 84% < 001
Yes (n = 124) 96% 100% 92% 99% 0.62
LVI      
No (n = 500) 97% 95% 83% 93% 0.007
Yes (n = 95) 96% 100% 100% 70% 0.001
Nuclear grade**      
1 or 2 (n = 197) 97% 100% 67% 100% 0.009
3 (n = 395) 97% 94% 88% 88% 0.04
  1. * In three patients the number of lymph nodes was unknown. ** In one patient, the nuclear grade was unknown. LRC, local-regional control; LVI, lymphovascular invasion; pCR, pathologic complete response